Cargando…
Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
AIM: To determine a dose response relationship of disintegration of a hyaluronic acid (HA) and hyaluronidase (HAS) used in prostate cancer radiotherapy. MATERIALS AND METHODS: Five in-vitro models are applicated with 3 ml (ml) HA. For dissolution varying doses of HAS were used: 6 ml, 3 ml, 1.5 ml, a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749177/ https://www.ncbi.nlm.nih.gov/pubmed/35036588 http://dx.doi.org/10.1016/j.ctro.2021.12.009 |
_version_ | 1784631171950313472 |
---|---|
author | Vanneste, Ben G.L. Lutgens, Ludy Van Limbergen, Evert J. |
author_facet | Vanneste, Ben G.L. Lutgens, Ludy Van Limbergen, Evert J. |
author_sort | Vanneste, Ben G.L. |
collection | PubMed |
description | AIM: To determine a dose response relationship of disintegration of a hyaluronic acid (HA) and hyaluronidase (HAS) used in prostate cancer radiotherapy. MATERIALS AND METHODS: Five in-vitro models are applicated with 3 ml (ml) HA. For dissolution varying doses of HAS were used: 6 ml, 3 ml, 1.5 ml, and 0 ml. One ml contains 150 International Units (IU). Each HAS was added with saline till the complementary amount of 6 ml. One phantom was solely implanted with a HA 3 ml acting as a control. Length, width and height were measured on different time points: 1st day 4 times, 2nd day 3 times, third day 2 times, and then once daily during one week, with a final measurement 2 weeks after implantation. The experiments were performed in duplicate to exclude variations and confirm the results. RESULTS: The fastest dissolution was observed with the highest concentration of HAS, already observed at the first time point 2 h after implantation, with volume decrease of 50% on the second day, and less than 1 ml residue (33%) on day 4. The 2 other concentrations of HAS also showed a volume decrease, with less than 2 ml (66%) on day 4. All the applied quantities of HAS are observed with a residue of less than 1 ml after 7 days. After 14 days the control phantom and the saline filled one remains on steady state volume (3 ml). CONCLUSIONS: A dose response was observed by HAS injection: highest volumes of HAS dissolute most swiftly. Using a ratio of HA:HAS of 1:2 results in a decrease to half of initial volume within 24 h. This is of special interest when used in clinical practice following erroneous positioning, and dissolution is urgently needed. |
format | Online Article Text |
id | pubmed-8749177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87491772022-01-13 Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model Vanneste, Ben G.L. Lutgens, Ludy Van Limbergen, Evert J. Clin Transl Radiat Oncol Technical Note AIM: To determine a dose response relationship of disintegration of a hyaluronic acid (HA) and hyaluronidase (HAS) used in prostate cancer radiotherapy. MATERIALS AND METHODS: Five in-vitro models are applicated with 3 ml (ml) HA. For dissolution varying doses of HAS were used: 6 ml, 3 ml, 1.5 ml, and 0 ml. One ml contains 150 International Units (IU). Each HAS was added with saline till the complementary amount of 6 ml. One phantom was solely implanted with a HA 3 ml acting as a control. Length, width and height were measured on different time points: 1st day 4 times, 2nd day 3 times, third day 2 times, and then once daily during one week, with a final measurement 2 weeks after implantation. The experiments were performed in duplicate to exclude variations and confirm the results. RESULTS: The fastest dissolution was observed with the highest concentration of HAS, already observed at the first time point 2 h after implantation, with volume decrease of 50% on the second day, and less than 1 ml residue (33%) on day 4. The 2 other concentrations of HAS also showed a volume decrease, with less than 2 ml (66%) on day 4. All the applied quantities of HAS are observed with a residue of less than 1 ml after 7 days. After 14 days the control phantom and the saline filled one remains on steady state volume (3 ml). CONCLUSIONS: A dose response was observed by HAS injection: highest volumes of HAS dissolute most swiftly. Using a ratio of HA:HAS of 1:2 results in a decrease to half of initial volume within 24 h. This is of special interest when used in clinical practice following erroneous positioning, and dissolution is urgently needed. Elsevier 2022-01-05 /pmc/articles/PMC8749177/ /pubmed/35036588 http://dx.doi.org/10.1016/j.ctro.2021.12.009 Text en © 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Technical Note Vanneste, Ben G.L. Lutgens, Ludy Van Limbergen, Evert J. Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
title | Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
title_full | Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
title_fullStr | Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
title_full_unstemmed | Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
title_short | Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
title_sort | evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model |
topic | Technical Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749177/ https://www.ncbi.nlm.nih.gov/pubmed/35036588 http://dx.doi.org/10.1016/j.ctro.2021.12.009 |
work_keys_str_mv | AT vannestebengl evaluationofhyaluronicacidgeldissolutionwithhyaluronidaseinaninvitroprostatecancermodel AT lutgensludy evaluationofhyaluronicacidgeldissolutionwithhyaluronidaseinaninvitroprostatecancermodel AT vanlimbergenevertj evaluationofhyaluronicacidgeldissolutionwithhyaluronidaseinaninvitroprostatecancermodel |